Get the Stockscreener App
0.33
4.30%
0.0136
After Hours:
.35
0.02
+6.06%
Virpax Pharmaceuticals Inc stock is traded at $0.33, with a volume of 959.16K.
It is up +4.30% in the last 24 hours and down -46.52% over the past month.
Virpax Pharmaceuticals Inc is a preclinical stage biopharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management. Its product portfolio includes Topical metered-dose spray; Liposomal in Hydrogel encapsulation; and Enkephalin Intranasal spray.
See More
Previous Close:
$0.3164
Open:
$0.316
24h Volume:
959.16K
Relative Volume:
0.30
Market Cap:
$2.67M
Revenue:
-
Net Income/Loss:
$-15.19M
P/E Ratio:
-0.2519
EPS:
-1.31
Net Cash Flow:
$-9.85M
1W Performance:
-17.50%
1M Performance:
-46.52%
6M Performance:
-37.51%
1Y Performance:
-90.71%
1-Day Range:
$0.316
$0.365
1-Week Range:
$0.31
$0.3974
52-Week Range:
$0.286
$5.48
Virpax Pharmaceuticals Inc Stock (VRPX) Company Profile
Name
Virpax Pharmaceuticals Inc
Sector
Industry
Phone
610-727-4597
Address
1055 WESTLAKES DRIVE, SUITE 300, BERWYN
Compare VRPX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRPX
Virpax Pharmaceuticals Inc
|
0.33 | 2.67M | 0 | -15.19M | -9.85M | -12.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Virpax Pharmaceuticals Inc Stock (VRPX) Latest News
Virpax Pharmaceuticals names new board director - Investing.com
Virpax Pharmaceuticals names new board director By Investing.com - Investing.com UK
Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Short Interest Update - Defense World
Virpax Pharmaceuticals announces board member resignation By Investing.com - Investing.com South Africa
Virpax Pharmaceuticals announces board member resignation - Investing.com
Virpax Pharmaceuticals stock hits 52-week low at $0.36 By Investing.com - Investing.com Canada
Virpax Pharmaceuticals stock hits 52-week low at $0.36 - Investing.com
Virpax Pharmaceuticals Extends Collaboration with NIH Center for Pain Management Innovation - MSN
VRPX (Virpax Pharmaceuticals) Enterprise Value : $3.71 Mil (As of Dec. 01, 2024) - GuruFocus.com
Virpax Pharmaceuticals lowers quorum requirement By Investing.com - Investing.com South Africa
Virpax Pharmaceuticals lowers quorum requirement - Investing.com India
Virpax Pharmaceuticals : Amendments to Bylaws Form 8 K - Marketscreener.com
Virpax Pharmaceuticals Announces Positive Results in Study for Long-Lasting Pain Relief Formulation - MSN
Virpax Pharmaceuticals regains Nasdaq compliance By Investing.com - Investing.com Nigeria
Virpax Pharmaceuticals regains Nasdaq compliance - Investing.com India
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Virpax Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements and Makes Key Appointments - Defense World
Virpax Pharmaceuticals Strengthens Leadership and Expands Collaborations - TipRanks
Maxim Group Downgrades Virpax Pharmaceuticals (VRPX) - MSN
Virpax Announces Positive Results for the Swine Model Dose Range Finding Study for Probudur - Marketscreener.com
Why Is Virpax Pharmaceuticals Stock Gaining On Friday? - Benzinga
Virpax Pharmaceuticals extends NIH pain management research By Investing.com - Investing.com Australia
Virpax Pharma Gets Government Cooperation Deal Extension - Marketscreener.com
Virpax Pharmaceuticals extends NIH pain management research - Investing.com India
Virpax Announces Agreement with the U.S. Department of Health and Human Services for the Developmental Extension for NES100 Towards IND for Acute and Chronic Non-Cancer Pain Alternative - The Bakersfield Californian
Virpax Extends NIH Partnership for Novel Non-Addictive Pain Treatment Technology | VRPX Stock News - StockTitan
VRPX (Virpax Pharmaceuticals) Debt-to-EBITDA : 0.00 (As of Sep. 2024) - GuruFocus.com
Virpax Pharmaceuticals appoints new CFO - Investing.com
Virpax Pharmaceuticals appoints new CFO By Investing.com - Investing.com Canada
Virpax Pharmaceuticals Announces New Chief Financial Officer - TipRanks
Virpax Pharmaceuticals, Inc. Appoints Usama Chaudhry as Chief Financial Officer - Marketscreener.com
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Virpax Pharmaceuticals, Inc.'s $5.0 Million Public Offering - The Manila Times
Spartan Capital Securities, LLC Serves as Sole Placement - GlobeNewswire
Virpax Pharmaceuticals Raises $5M to Advance Pain Management Drug Development | VRPX Stock News - StockTitan
Virpax Pharmaceuticals Inc. (VRPX) Quarterly 10-Q Report - Quartzy
Virpax Pharmaceuticals Prices of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants - citybiz
Virpax Pharmaceuticals prices $5 million stock offering - Investing.com
Virpax Pharmaceuticals prices $5 million stock offering By Investing.com - Investing.com UK
Virpax Pharmaceuticals Raises $5M in Public Offering to Advance Pain Management Drug | VRPX Stock News - StockTitan
Adial Pharma Taps Veteran CFO with $150M+ Fundraising Track Record - StockTitan
Closing Bell Recap: Virpax Pharmaceuticals Inc (VRPX) Ends at 0.48, Reflecting a 1.06 Upturn - The Dwinnex
Virpax Pharmaceuticals Inc: Navigating a Turbulent Year, Up -95.58% from 52-Week Low - The InvestChronicle
VRPX stock touches 52-week low at $0.46 amid market challenges - Investing.com India
Virpax Pharmaceuticals Inc Stock (VRPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):